Hongmei Bai
- Microbiology top 2%
- Antimicrobial Peptides and Activities 3
- Bacterial Infections and Vaccines 3
- Molecular Medicine top 5%
- Endocrinology top 5%
-
- Immunotherapy and Immune Responses 9
- Biotechnology top 10%
-
- Nanoplatforms for cancer theranostics 4
-
- SARS-CoV-2 and COVID-19 Research 3
-
- RNA Interference and Gene Delivery 2
-
- Advanced Nanomaterials in Catalysis 2
-
- Parasites and Host Interactions 2
Hongmei Bai
29 papers receiving 659 citations
Peers
Comparison fields: 5 of 74
- Microbiology 208
- Molecular Medicine 124
- Endocrinology 98
- Immunology 180
- Biotechnology 56
Countries citing papers authored by Hongmei Bai
This map shows the geographic impact of Hongmei Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongmei Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongmei Bai more than expected).
Fields of papers citing papers by Hongmei Bai
This network shows the impact of papers produced by Hongmei Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongmei Bai. The network helps show where Hongmei Bai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hongmei Bai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 5 | |
| 4 | 2022 | 4 | |
| 5 | 2022 | 4 | |
| 6 | 2021 | 14 | |
| 7 | 2021 | 13 | |
| 8 | 2020 | 8 | |
| 9 | 2019 | 18 | |
| 10 | 2019 | 17 | |
| 11 | 2019 | 46 | |
| 12 | 2017 | 9 | |
| 13 | 2017 | 61 | |
| 14 | 2016 | 101 | |
| 15 | 2016 | 99 | |
| 16 | 2016 | 2 | |
| 17 | 2015 | 17 | |
| 18 | 2015 | 7 | |
| 19 | 2015 | 13 | |
| 20 | 2011 | 0 |
About Hongmei Bai
Hongmei Bai is a scholar working on Microbiology, Immunology, Molecular Medicine, Parasitology and Software, having authored 31 papers that have together received 669 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (9 papers), Nanoplatforms for cancer theranostics (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Antimicrobial Peptides and Activities (3 papers), Bacterial Infections and Vaccines (3 papers), RNA Interference and Gene Delivery (2 papers), Advanced Nanomaterials in Catalysis (2 papers) and Parasites and Host Interactions (2 papers). The work is most often cited by research in Microbiology (208 citations), Molecular Medicine (124 citations), Endocrinology (98 citations), Immunology (180 citations) and Biotechnology (56 citations). Hongmei Bai has collaborated with scholars based in China, Singapore and Canada. Frequent co-authors include Weiwei Huang, Wenjia Sun, Yanbing Ma, Cunbao Liu, Xu Yang, Yufeng Yao, Shijie Wang, Xiaojie Chu, Yang Li and Yang Xu. Their work appears in journals such as Scientific Reports, Human Vaccines & Immunotherapeutics, Nanomedicine Nanotechnology Biology and Medicine, International Journal of Nanomedicine and Advanced Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.